Nureca Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Fri Apr 17 2026

Nureca (NSE: NURECA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Nureca trading at Rs 320 — against a 52-week high of Rs 610 and a 1-year return of -42% — the Q4 FY26 results will be a pivotal event for investors in the Consumer Health sector.

Analyst estimates for Q4 FY26 revenue stand at Rs 90–105 Cr, with PAT expectations of Rs 8–12 Cr and margin projections of EBITDA 10–13%. This article covers the Nureca Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.

Get free investment predictions and live Q4 result alerts on Univest.

Table of Contents

Nureca Q4 Results 2026 Date

Company	Q4 FY26 Results Date	Sector
TCS	April 9, 2026	IT Services
Infosys	April 23, 2026	IT Services
Nureca	May 2026 (Expected)	See article

Nureca has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet on this date to approve the audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a current market price of Rs 320, investors and analysts are closely watching this announcement for revenue growth confirmation and FY27 guidance.

Why This Quarter Matters

Q4 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Nureca, which operates in the Consumer Health sector, Q4 FY26 will reveal whether momentum from earlier quarters has been sustained and whether management’s strategic initiatives have translated into financial outcomes.

At a 1-year return of -42%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can begin a recovery. Investors will watch for order pipeline updates, margin trajectory, and capex guidance — any positive surprise on multiple parameters could drive a meaningful post-results re-rating.

Nureca Q4 FY26 Earnings Estimates

Nureca Q4 FY26 Analyst Estimates at a Glance | Source: MOFSL, YES Securities, JM Financial

Access premium SEBI-registered research on Univest.

Analysts covering Nureca have published Q4 FY26 estimates based on Q3 FY26 actuals, sector trends, and company-specific catalysts. Consensus estimates point to revenue of Rs 90–105 Cr, PAT of Rs 8–12 Cr, and margins of EBITDA 10–13%. These projections reflect both the seasonal strength of Q4 and ongoing structural improvements in Nureca’s business model.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate
Revenue	Rs 82 Cr	Rs 90–105 Cr
PAT	Rs 7.2 Cr	Rs 8–12 Cr
Margin	EBITDA 10.5%	EBITDA 10–13%
Growth Driver	Base quarter	Growth catalyst
Dividend	Nil	Nil expected

Beyond headline numbers, investors will closely monitor FY27 guidance commentary, order book evolution, working capital trends, and any one-time items that could inflate or suppress reported PAT. A clean recurring profit print is more positively received by the market than results driven by non-operational gains.

Screen Nureca fundamentals on Univest Screener.

5 Key Factors That Will Drive Nureca Q4 FY26 Performance

D2C Health Device Recovery

Nureca’s D2C portfolio of health monitoring devices — including blood pressure monitors, glucometers, and thermometers — saw strong pandemic-era demand which has since normalised. Q4 FY26 will reveal whether the company has successfully repositioned its sales channels through offline expansion and institutional tie-ups. Management has been focused on building a premium brand perception in the health-tech space, which could drive ASP (average selling price) improvement and better gross margins in the coming quarters.

Offline Distribution Expansion

Nureca has been aggressively expanding its offline retail presence beyond its initial online-first model. Partnerships with modern trade chains and pharmacy networks are expected to contribute meaningfully to Q4 FY26 revenue. Offline channels typically command better margins due to reduced platform fee dependency. Any evidence of accelerating offline revenue share would be viewed as a strong positive structural signal by analysts.

International Markets & Export Push

Nureca has been exploring exports to Southeast Asia and the Middle East as part of its medium-term growth strategy. Q4 results will provide an update on progress in these new geographies. Export revenues, even if small in absolute terms, carry strong margin potential given the premiumisation of health devices in emerging markets and reduced domestic competitive pressure in international channels.

Operating Leverage from Fixed Cost Base

As revenue scales, Nureca’s fixed cost base — including its warehousing, tech platform, and brand spend — provides operating leverage potential. Q4 FY26 revenue at the upper end of the Rs 90–105 Cr estimate range would meaningfully improve EBITDA margins beyond the 13% level and demonstrate the scalability of the business model for investors looking at the FY27 growth trajectory.

New Product Launches and Category Expansion

Nureca has been expanding into adjacent health categories including fitness trackers, smart scales, and pain management devices. Q4 FY26 will reflect the initial revenue contribution from newer SKUs launched in H2 FY26. Successful category expansion reduces dependence on any single product line and improves the overall revenue quality and repeatability of the business.

5 Risks to Watch in Nureca Q4 FY26

D2C Market Competition

The online health device market in India has seen intensifying competition from both global brands (Omron, Beurer) and domestic entrants. Margin pressure from promotional spend and price competition could weigh on Nureca’s Q4 FY26 gross margins despite revenue growth.

Post-Pandemic Demand Normalisation

Health device demand surged during COVID-19 but has moderated post-pandemic. Nureca must demonstrate it can grow revenues in a normalised environment, which may require higher marketing investment and channel discounts that compress margins.

Supply Chain and Import Dependency

Nureca sources components primarily from China and imports finished devices. Rupee depreciation or US-China trade tensions causing supply chain disruptions could increase input costs and hurt gross margins in Q4 FY26.

Platform Concentration Risk

A significant portion of Nureca’s revenues historically came from Amazon and Flipkart. Platform fee increases or algorithmic changes affecting product visibility could impact revenues and margins in a single quarter significantly.

Working Capital and Inventory Build

Health device companies face seasonal inventory build before high-demand periods. If Q4 sell-through is below expectations, inventory write-downs or elevated working capital could pressure free cash flow and balance sheet quality.

Nureca Share Price and Analyst Ratings

Nureca Share Price & Analyst Ratings | Source: NSE/BSE, Broker Notes

Nureca is trading at Rs 320 as of early April 2026, against a 52-week high of Rs 610 and 52-week low of Rs 275. Market cap stands at Rs 960 Cr. The 1-year return of -42% reflects sector headwinds alongside company-specific factors. Analyst price targets range from the conservative to the optimistic, reflecting differing views on the pace of business recovery and margin expansion.

Brokerage	Rating	Target Price	Thesis
MOFSL	Neutral	Rs 380	Margin recovery; watch D2C
YES Securities	Buy	Rs 450	Health device upcycle
JM Financial	Neutral	Rs 370	Channel expansion key

Download the Univest iOS App or Univest Android App to track Nureca’s live price and receive real-time Q4 result alerts.

Conclusion

Nureca’s Q4 FY26 results will test whether the company’s shift toward offline channels and international markets is gaining traction. At Rs 320, the stock is trading significantly below its 52-week high of Rs 610, reflecting investor concern about post-pandemic demand normalisation. A revenue print at the upper end of Rs 90–105 Cr with improving EBITDA margins would likely trigger a re-rating. Investors should watch closely for FY27 guidance on new product launches and the offline channel ramp. Consult a SEBI-registered advisor before investing.

This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.

For more Q4 FY26 previews across IT, banking, auto, pharma, and cement sectors, visit Univest Blogs.

Frequently Asked Questions

What is the Nureca Q4 results 2026 date?

Nureca Q4 FY26 results are scheduled for May 2026 (Expected). The board of directors will meet on this date to approve the audited financial statements and consider a dividend recommendation for FY26.

What is the Nureca Q4 FY26 PAT estimate?

Analysts estimate Nureca Q4 FY26 net profit (PAT) in the range of Rs 8–12 Cr. This estimate is based on revenue assumptions of Rs 90–105 Cr and a margin of EBITDA 10–13%. Actual results may differ from these consensus estimates.

What is Nureca’s share price ahead of Q4 results?

Nureca shares are trading at approximately Rs 320 as of early April 2026. The 52-week high is Rs 610 and the 52-week low is Rs 275. The one-year return is -42% and the market cap stands at Rs 960 Cr.

Will Nureca declare a dividend in Q4 2026?

Nureca is expected to consider a dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected). The quantum signals management’s confidence in free cash flow generation for FY26.

Which analysts have a Buy rating on Nureca?

YES Securities (target Rs 450) have positive ratings on Nureca ahead of Q4 FY26 results.

What were Nureca Q3 FY26 results?

In Q3 FY26, Nureca reported revenue of Rs 82 Cr and PAT of Rs 7.2 Cr, with margins at EBITDA 10.5%. These numbers provided the base for Q4 FY26 estimates and analyst coverage updates.

When do Infosys and TCS announce Q4 results 2026?

TCS announced Q4 FY26 results on April 9, 2026. See the full TCS Q4 Results 2026 preview. Infosys announced Q4 FY26 results on April 23, 2026.

Is Nureca a good investment ahead of Q4 results?

Nureca at Rs 320 offers a risk-reward that depends on Q4 execution and FY27 guidance. Investors should review the analyst estimates, monitor the results announcement, and consult a SEBI-registered advisor before making investment decisions. Past performance is not indicative of future results.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.